)
Rossari Biotech (ROSSARI) investor relations material
Rossari Biotech Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 FY26 revenue grew 18% year-over-year, driven by strong volume expansion across HPPC, TSC, and AHN segments, with exports rising 36% and now accounting for 28% of total revenue.
Profitability remained steady despite subdued pricing, margin pressures, and one-time expenses, supported by new product development in green chemistry and advanced formulations.
Management remains confident in future profitability as new initiatives and capacity expansions begin to contribute to revenues.
Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved and reviewed by the Board and Audit Committee.
Statutory auditors conducted a limited review and found no material misstatements in the results.
Financial highlights
Q2 FY26 consolidated revenue: ₹5,861.07 million, up from ₹4,983.51 million in Q2 FY25; standalone revenue: ₹4,195.12 million, up from ₹3,359.89 million.
Q2 FY26 EBITDA: ₹71.9 crore, margin at 12.3% (down from 13.2% last year); PAT: ₹36.9 crore, margin at 6.3%.
H1 FY26 consolidated revenue: ₹11,298.23 million, up from ₹9,880.01 million; H1 PAT: ₹704.72 million, up from ₹702.32 million.
Institutional and B2C businesses grew modestly, with reduced losses and operational improvements.
Net working capital increased to 102 days, mainly due to stretched receivables and strategic inventory stocking.
Outlook and guidance
Margin guidance for core B2B business remains at 14–16% EBITDA for H2 FY26, with expected improvement as new capacities reach full utilization and EO availability improves.
Revenue ramp-up anticipated from new non-EO product lines and international expansion, though margin and sales outlook remain cautious due to global uncertainties and tariff pressures.
Management expects profitability to improve as investments in new business lines begin to yield results.
Additional investment of up to USD 8 million approved for Saudi Arabia subsidiary to support business expansion, to be completed by March 31, 2027.
Next Rossari Biotech earnings date
Next Rossari Biotech earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)